Exelixis | Les Charges D'Exploitation



Operating Expenses Changement Date
Acadia Pharmaceuticals USD 225.03M 118.93M 2025-03
Agios Pharmaceuticals USD 115.35M 20.41M 2025-03
Amgen USD 6.86B 85M 2025-03
AstraZeneca USD 9.91B 2.94B 2025-03
Bayer EUR 8.2B 5.59B 2024-12
BioMarin Pharmaceutical USD 521.25M 64.65M 2025-03
Bristol-Myers Squibb USD 8.23B 3.32B 2025-03
Cytokinetics USD 157.21M 1.24M 2025-03
Eisai JPY 188.58B 7.01B 2024-12
Eli Lilly USD 7.32B 1.06B 2025-03
Exelixis USD 403.55M 82K 2025-01
Genmab DKK 4.25B 812M 2024-12
Glaxosmithkline GBP 7.42B 408M 2024-12
Incyte USD 847.73M 29.46M 2025-03
Ionis Pharmaceuticals USD 278M 59.4M 2025-03
MacroGenics USD 35.94M 20.58M 2024-12
Merck USD 9.66B 1.67B 2025-03
Moderna USD 1.16B 1.06B 2025-03
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Novartis USD 11.28B 1.73B 2024-12
Pfizer USD 10.05B 8.12B 2025-03
Sanofi EUR 6.77B 3.75B 2024-12
Takeda JPY 1.08T 85.39B 2024-12
Ultragenyx Pharmaceutical USD 282.23M 4.92M 2025-03
Xencor USD 75.91M 9.94M 2025-03



Exelixis Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.